COX-2 selective inhibitors and heart health.
On September 30, 2004, because of an observed increased risk of serious cardiovascular (CV) events, Merck & Co, Inc, voluntarily withdrew rofecoxib from the worldwide market. The withdrawal has focused attention on the possible class effect on the cardiovascular system of the other currently available cyclooxygenase-2 (COX-2) selective inhibitors: celecoxib and valdecoxib. This review evaluates and differentiates the CV effects of COX-2 selective inhibitors through an assessment of prospective, randomized epidemiologic studies and meta-analyses.
Simon
Lee S
LS
Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, USA.
White
William B
WB
D000328:Adult; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D002648:Child; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D011446:Prospective Studies; D011720:Pyrazoles / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects*; D000096926:Benzenesulfonamides
D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides